Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001208815 | SCV001380223 | pathogenic | Bardet-Biedl syndrome | 2022-06-09 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 939414). This variant has not been reported in the literature in individuals affected with BBS2-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.002%). This sequence change creates a premature translational stop signal (p.Phe147Serfs*54) in the BBS2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BBS2 are known to be pathogenic (PMID: 11285252, 20177705, 24608809, 26518167). |
Prevention |
RCV004538446 | SCV004117123 | likely pathogenic | BBS2-related disorder | 2023-06-13 | criteria provided, single submitter | clinical testing | The BBS2 c.440delT variant is predicted to result in a frameshift and premature protein termination (p.Phe147Serfs*54). To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0023% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/16-56545101-GA-G). Frameshift variants in BBS2 are expected to be pathogenic. This variant is interpreted as likely pathogenic. |
Baylor Genetics | RCV003462697 | SCV004214020 | likely pathogenic | Bardet-Biedl syndrome 2 | 2023-08-03 | criteria provided, single submitter | clinical testing |